Betamethasone Valerate
drugOn this page
Also known as AudavateAudavate rdBeta-valBetacapBetadermBetameth val in coal tarBetamethasone (as valerate)Betamethasoni valerasBetatrexBetesilBetnovate rdBetnovate-cBetnovate-nBettamousseBextasolDermabetFucibetLuxiqNSC-755912
Summary
Betamethasone Valerate (CHEMBL1497) is an approved small-molecule anti-inflammatory drug; indicated across 7 conditions including skin disorder and atopic eczema.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 7 conditions
- Clinical trials: 17
- Chemistry: 476.6 Da · C27H37FO6
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1497 |
| Name | Betamethasone Valerate |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 16533 |
| ChEBI | CHEBI:31277 |
| Molecular formula | C27H37FO6 |
| Molecular weight | 476.6 |
| InChIKey | SNHRLVCMMWUAJD-SUYDQAKGSA-N |
SMILES: CCCCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)C(=O)CO
IUPAC name: [(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] pentanoate
ChEBI definition: A steroid ester that is betamethasone in which the hydroxy group at the 17α position has been converted to the corresponding pentanoate ester.
Pharmacological roles (ChEBI): anti-inflammatory drug.
Also known as: Audavate, Audavate rd, Beta-val, Betacap, Betaderm, Betameth val in coal tar, Betamethasone (as valerate), Betamethasone valerate, Betamethasoni valeras, Betatrex, Betesil, Betnovate rd
Patent coverage: 5,151 distinct patent families (17,390 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Glucocorticoid receptor, Progesterone receptor, Androgen receptor.
Bioactivity
ChEMBL activities: 3 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| NR3C1 | 8.4 | AC50 | 4 | nM | CHEMBL_ACT_25175629 |
| PGR | 6.89 | AC50 | 130 | nM | CHEMBL_ACT_25192724 |
| P15207 | 5.62 | AC50 | 2400 | nM | CHEMBL_ACT_25187314 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
7 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| skin disorder | 4 | MONDO:0005093 | EFO:0000701 |
| atopic eczema | 3 | MONDO:0004980 | EFO:0000274 |
| oral submucous fibrosis | 3 | MONDO:0018166 | EFO:1001818 |
| paronychia | 3 | MONDO:0005898 | EFO:0007421 |
| psoriasis | 1 | MONDO:0005083 | EFO:0000676 |
| alopecia areata | 1 | MONDO:0005340 | EFO:0004192 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 17.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 4 |
| PHASE1 | 4 |
| Not specified | 4 |
| PHASE4 | 3 |
| PHASE2/PHASE3 | 1 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07508124 | PHASE4 | RECRUITING | Topical Steroids to Prevent Recurrent Urinary Tract Infections in Uncircumcised Male Infants: a Pilot Study |
| NCT00576550 | PHASE4 | COMPLETED | A Randomised Trial of a Moisturising Cream in Preventing Recurrence of Hand Eczema |
| NCT05555797 | PHASE4 | UNKNOWN | Excimer Laser With Topical Agents in Psoriasis Vulgaris |
| NCT05535738 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation |
| NCT06643416 | PHASE3 | RECRUITING | Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia |
| NCT00576238 | PHASE3 | COMPLETED | Skin Tolerance Study of Betamethasone Creams in Atopic Eczema and the Preventative Properties of a Moisturiser |
| NCT04476420 | PHASE3 | COMPLETED | Comparative Effect of Nigella Sativa and Conventional Management for OSMF |
| NCT06140186 | PHASE3 | UNKNOWN | Efficacy and Safety of Timolol for TKI Induced Paronychia |
| NCT04194814 | PHASE2 | COMPLETED | Skin bioMARkers for Atopic Eczema Therapy Evaluation |
| NCT00358384 | PHASE1 | COMPLETED | Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034 |
| NCT01646567 | PHASE1 | COMPLETED | SHP-141C in Plaque Type Psoriasis |
| NCT02548052 | PHASE1 | COMPLETED | Study of Safety and Efficacy of Topical GSK2981278 Ointment in Plaque Psoriasis |
| NCT06087796 | PHASE1 | UNKNOWN | Topical Pentoxifylline; Metformin Versus Betamethasone in the Treatment of Alopecia Areata. |
| NCT07366268 | Not specified | NOT_YET_RECRUITING | Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis |
| NCT00608673 | Not specified | COMPLETED | Comparing the Therapeutic Efficacy of Pimecrolimus Cream With Betamethasone Cream for Discoid Lupus Erythematosus |
| NCT05803070 | Not specified | UNKNOWN | Topical Cetirizine in Treatment of Localized Alopecia Areata |
| NCT06267066 | Not specified | UNKNOWN | Fractional Carbon Dioxide Laser: A Novel Therapeutic Option for Lichen Simplex Chronicus |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: skin disorder, atopic eczema, oral submucous fibrosis, paronychia